In 2011, vemurafenib, a small molecule inhibitor that targets the most common mutation in melanoma, B-Raf proto-oncogene, serine/threonine kinase (BRAFV600E), became the first drug since interleukin (IL)-2 therapy to show improvement in treating melanoma [3,4,5]. This evidence concerns the gene MARK2 and melanoma.